

Rasagiline-Trima Tablets

Active ingredient and its quantity:

Each tablet contains Rasagiline (as mesylate) 1 mg
Inactive ingredients: see section 6 "Further Information".

Read this leaflet carefully in its entirety before using the medicine.
This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist.

This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar.

This medicine is not intended for children and adolescents under 18 years of age.

1. WHAT IS THE MEDICINE INTENDED FOR?

For the treatment of Parkinson's disease as a monotherapy, or in combination with Levodopa.

Therapeutic group:

Selective Monoamine Oxidase-B inhibitors - MAO B

2. BEFORE USING THE MEDICINE

X Do not use the medicine:

- If you are allergic (hypersensitive) to the active ingredient or any of the other ingredients of the medicine (see section 6).
- While taking pethidine (a strong pain killer), monoamine oxidase (MAO) inhibitors (for treatment of depression or Parkinson's disease, or used for any other indication, including natural products and medicinal products without prescription e.g. St. John's Wort for depression). You must wait at least 14 days after stopping Rasagiline-Trima treatment and before starting treatment with MAO inhibitors or pethidine (pain killer).
- If you are suffering from severe liver failure.

▲ Special warnings regarding the use of the medicine

▲ Before using this medicine, tell the doctor:

- If you have mild to moderate liver problems.
- If you notice any suspicious skin changes.
- Tell your doctor if you or your family/carer notice that you are developing unusual behaviors where you cannot resist the impulse, urges or cravings to carry out harmful or detrimental activities to yourself or others. These are called impulse control disorders.

In patients taking this medicine alone or together with other medications used to treat Parkinson's disease, behaviors disorders such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive abnormal behavior and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed. Your doctor may consider to adjust your dose or stop the medicine.

▲ If you are taking or have recently taken other medicines, including non-prescription medications and nutritional supplements, tell the doctor or pharmacist.

In particular, inform the doctor if you are taking the following medicines:

- Antidepressants medicines (e.g. tricyclic, tetracyclic, selective serotonin reuptake inhibitors {SSRIs}, selective serotonin-norepinephrine reuptake inhibitors {SNRIs}, monoamine oxidase (MAO) inhibitors).
- Ciprofloxacin (used against infections).
- Dextromethorphan (cough suppressant).
- Sympathomimetics medicines such as those present in eye drops, nasal and oral decongestants or cold medicine containing ephedrine or pseudoephedrine.
- Use of this medicine simultaneously with antidepressants containing fluoxetine or fluvoxamine should be avoided. If you are starting treatment with Rasagiline-Trima, you should wait at least 5 weeks after stopping fluoxetine treatment. On the other hand, if you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline-Trima treatment.
- Pethidine- see section 2 "Do not use the medicine".
- Levodopa – There have been reports on cases of increase in side effects of Levodopa, as well as exacerbation of involuntary repeated movements (dyskinesia) and blood pressure reduction due to the combination of Rasagiline-Trima and Levodopa.

▲ Using the medicine and food

The medicine may be taken with or without food.

▲ Pregnancy and breastfeeding

If you are pregnant, planning to become pregnant or are breastfeeding, consult a doctor before using the medicine.

▲ Children

The medicine is not intended for children and adolescents under 18 years of age.

▲ Driving and using machines

In the absence of data regarding the effect of the medicine, consult the doctor prior to driving or using dangerous machines.

▲ Smoking

Inform the doctor if you are a smoker or intend to quit smoking.

3. HOW SHOULD YOU USE THE MEDICINE?

Always use this medicine according to the doctor's instructions. You should check with the doctor or the pharmacist if you are unsure.

The dosage and treatment regimen will be determined by the doctor only.

The usual dosage is generally:

One tablet per day with or without food.

Use this medicine at scheduled times as determined by your attending doctor.

Do not exceed the recommended dose

Do not chew! Swallow the tablet whole with water.

If you accidentally took an overdose

If you took an overdose, or if a child accidentally swallowed the medicine, immediately refer to a doctor or proceed to a hospital emergency room and bring the package of the medicine with you.

If you forgot to take this medicine at the designated time, take the next dose at the usual time. Do not take two doses together to make up for the forgotten dose.

Adhere to the treatment as recommended by the doctor, even if there is an improvement in your health.

Do not stop treatment without consulting the doctor.

Do not take medicines in the dark! Check the label and the dose each time you take the medicine. Wear glasses if you need them.

If you have further questions regarding the use of the medicine, consult the doctor or pharmacist.

4. SIDE EFFECTS

As with any medicine, the use of Rasagiline-Trima may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not suffer from any of them.

The frequency of side effects observed in controlled clinical trials with a preparation containing the active substance rasagiline vs. placebo are defined as follows:

Very common side effects – occur in more than one user out of ten:

- dyskinesia (abnormal movements)
- headache

Common side effects – occur in 1-10 users out of 100:

- abdominal pains
- falls
- allergic reactions
- fever
- flu (influenza) syndrome
- feeling of being unwell
- neck pains
- chest pain (angina pectoris)
- low blood pressure when rising to a standing position. Symptoms like dizziness may occur
- decreased appetite
- constipation
- dry mouth
- nausea and vomiting
- flatulence
- leucopenia (low quantity of white blood cells)
- joint pains
- muscle pains
- joint inflammation (arthritis)
- numbness and muscle weakness of the hand (Carpal Tunnel syndrome)
- decreased weight
- abnormal dreams
- difficulty in muscular coordination (balance disorder)
- depression
- dizziness (vertigo)
- prolonged muscle contractions (dystonia)
- inflammation of nasal mucosa, runny nose (rhinitis)
- irritation of the skin (dermatitis)
- rash
- conjunctivitis (red eyes)
- urinary urgency

Uncommon side effects – occur in 1-10 users out of 1,000

- stroke (cerebrovascular accident)
- myocardial infarction
- blistering rash

In addition, skin cancer cases were reported in around 1% of patients in controlled clinical trials vs. placebo. Nevertheless, and according to data that has been collected, high risk of skin cancer (not exclusively melanoma) is associated with Parkinson's disease and not with any medicine in particular. In case of appearance of a suspected skin lesion, consult a specialist.

During Parkinson's disease, symptoms of hallucinations and confusion may appear. In post marketing follow-up performed for preparation containing the active substance rasagiline, these symptoms have also been observed in Parkinson's disease patients treated with preparations containing this active substance.

There have been cases of patients who, while taking one or more medications for the treatment of Parkinson's disease, were unable to resist the impulse or temptation to perform actions that could be harmful or detrimental to themselves or others. These are called impulse control disorders.

In patients taking tablets that contain the active ingredient rasagiline and/or other medications used to treat Parkinson's disease, the following signs have been observed:

Obsessive thoughts or impulsive behavior.

Strong impulse to gamble excessively despite serious personal or family consequences.

Altered or increased sexual impulse and behavior of significant concern to you or to others, for example, an increased sexual desire.

Uncontrolled excessive shopping or spending.

If you notice any of these behaviors you must tell your doctor, he will consider how to neutralize or reduce these effects.

If a side effect occurs, if any of the side effects worsen, or if you suffer from a side effect not mentioned in the leaflet, consult the doctor.

Reporting side effects

Side effects can be reported to the Ministry of Health (MoH) by clicking on the "Report on side effects due to medication therapy" link on the MoH home page (www.health.gov.il) which refers to the online form for side effects reporting, or by entering the link:

<https://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.gov.il>

Side effects can be also reported by email: safety@trima.co.il

5. HOW SHOULD THE MEDICINE BE STORED?

- Avoid poisoning! This medicine and any other medicine must be kept in a close place out of the reach of children and/or infants to avoid poisoning. Do not induce vomiting without explicit instruction from the doctor.
- Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month.
- Store in the original package, at a temperature below 25°C.

6. FURTHER INFORMATION

In addition to the active ingredient, the medicine also contains: Mannitol, maize starch, pregelatinized starch, stearic acid, colloidal silicon dioxide.

• What does the medicine look like and what are the contents of the package?

A white round tablet, convex on both sides. Each pack contains 10 or 30 tablets packed in blisters (not all pack types are necessarily marketed).

• **Manufacturer and registration holder:** Trima Israel Pharmaceutical Products Maabarot Ltd. Maabarot 4023000, Israel.

• This leaflet was checked and approved by the Ministry of Health in: March 2016.

• Registration number of the medicine in the National Drug Registry of the Ministry of Health: 155-62-34403-00

0316A
Maabarot 4023000
Israel Pharmaceutical Products
Maabarot Ltd.

